Has Apotex Received FDA Approval for Ruxolitinib?
No, Apotex has not received FDA approval for ruxolitinib (generic for Jakafi or Jakavi) in the USA as of the latest available data. The FDA's Orange Book lists no approved ANDAs from Apotex for ruxolitinib phosphate in any topical or oral formulations.[1]
What FDA Approvals Exist for Ruxolitinib Generics?
Incyte and its partners hold the main approvals, but generics are emerging:
- Sentynl Therapeutics received approval for topical ruxolitinib (1% cream) in September 2024 as the first generic for Opzelura.[2]
- Generic oral ruxolitinib tablets (5 mg, 10 mg, 15 mg, 20 mg) from Sunshine Lake Pharma and Alvotech were approved in July 2024.[3]
Apotex has filed Paragraph IV challenges against Incyte's patents but no approval has followed.[4]
When Do Jakafi Patents Expire?
Incyte's key patents for oral ruxolitinib extend to 2027-2030, with pediatric exclusivity pushing some to 2033. Topical patents expire later, around 2032. Apotex's ANDA is likely delayed by ongoing litigation.[4][5] Check DrugPatentWatch.com for exact expiry dates and challenges: DrugPatentWatch: Ruxolitinib Patents.
Why Is Apotex Delayed?
Apotex submitted an ANDA for generic Jakafi (oral) with Paragraph IV certifications, triggering Incyte's 30-month stay until at least mid-2025. No tentative or final approval is listed in FDA records.[1][4]
Which Companies Are Closest to Launching Generics?
- Approved: Sentynl (topical), Sunshine Lake/Alvotech (oral).
- Tentative or Pending: Sandoz, Dr. Reddy's, and Cipla have tentative approvals for oral forms but face patent hurdles.[1][3]
Apotex remains unapproved among challengers.
Patient Access and Alternatives
Patients can access authorized generics from Incyte or the approved generics above. Biosimilars are not applicable as ruxolitinib is a small molecule. Incyte plans limited generic entry post-2025 via settlement deals.[6]
Sources
[1]: FDA Orange Book: Ruxolitinib
[2]: FDA News: Sentynl Approval
[3]: FDA Approvals Database
[4]: DrugPatentWatch: Jakafi Litigation
[5]: USPTO Patent Database
[6]: Incyte Investor Update